Verici Dx plc (AIM:VRCI)
0.2250
0.00 (0.00%)
Sep 11, 2026, 3:44 PM GMT
Verici Dx Revenue
In the year 2025, Verici Dx had annual revenue of $3.66M USD with 9.73% growth. Verici Dx had revenue of $1.75M in the half year ending December 31, 2025, with 76.16% growth.
Revenue
$3.66M
Revenue Growth
+9.73%
P/S Ratio
1.89
Revenue / Employee
$203.56K
Employees
18
Market Cap
5.15M GBP
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.66M | 325.00K | 9.73% |
| Dec 31, 2024 | 3.34M | 2.33M | 229.62% |
| Dec 31, 2023 | 1.01M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 46.25B |
| GSK plc | 33.20B |
| Haleon | 11.15B |
| Smith & Nephew | 4.77B |
| Proteome Sciences | 3.76M |
| GENinCode | 3.08M |
| CRISM Therapeutics | 231.00K |
| Thalia Therapeutics | 7.26K |
Verici Dx News
- 2 months ago - Verici Dx Earnings Call Transcript: H2 2025 - Transcripts
- 2 months ago - Verici Dx Annual report: H2 2025 - Filings
- 2 months ago - Verici Dx Annual report: H2 2025 - Filings
- 2 months ago - Verici Dx Slides: H2 2025 - Filings
- 2 months ago - Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test - Business Wire
- 2 months ago - Verici Dx Collaborators to Present Data on Predictive Value of Tutivia™ for Acute Kidney Transplant Rejection at ATC 2026 - Business Wire
- 3 months ago - CORRECTING and REPLACING Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients - Business Wire
- 3 months ago - Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients - Business Wire